Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.

Published on May 22, 2021in American Journal of Hypertension2.669
· DOI :10.1093/AJH/HPAA192
Robert D. Brook64
Estimated H-index: 64
(UM: University of Michigan),
Niko Kaciroti54
Estimated H-index: 54
(UM: University of Michigan)
+ 5 AuthorsAccomplish investigators1
Estimated H-index: 1
BACKGROUND The 2017 hypertension guidelines lowered systolic blood pressure (BP) goals to <130 mm Hg and redefined resistant hypertension. We investigated if these changes alter the cardiovascular benefits demonstrated by combining a calcium channel blocker (CCB), rather than hydrochlorothiazide (HCTZ), with an angiotensin-converting enzyme inhibitor (ACEI). METHODS In this post hoc analysis of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension trial (n = 11,506), we compared the primary composite outcome (cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization) between the 2 combination-treatment limbs in patients achieving a systolic BP ≤130 mm Hg and those with "apparent resistant hypertension" (prescribed ≥4 antihypertensive medications). RESULTS Among study patients, 5,221 (45.4%) achieved a systolic BP ≤130 mm Hg. There were fewer primary endpoints in the amlodipine/benazepril (9.2%) vs. the HCTZ/benazepril (10.9%) limb (adjusted hazard ratio [HR] 0.83, 95% confidence interval [CI], 0.70-0.99). There were also fewer primary endpoints in the amlodipine/benazepril (12.8%) vs. the HCTZ/benazepril (15.2%) limb (n = 4,451, 38.7%) among patients with apparent resistant hypertension (HR 0.81, 95% CI, 0.70-0.95). CONCLUSIONS Combination therapy adding a CCB, rather than HCTZ, to an ACEI was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic BP targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination. CLINICAL TRIALS REGISTRATION Trial Number NCT00170950.
#1Giuseppe Mancia (University of Milano-Bicocca)H-Index: 166
#2Federico Rea (University of Milano-Bicocca)H-Index: 50
Last. Guido Grassi (University of Milano-Bicocca)H-Index: 100
view all 4 authors...
Blood pressure (BP) control in patients with hypertension is variable worldwide, and in general, it results largely unsatisfactory. Factors responsible for this phenomenon include insufficient nati...
26 CitationsSource
#1Dike B. Ojji (University of Abuja)H-Index: 19
#2Bongani M. Mayosi (Imperial College London)H-Index: 5
Last. Neil Poulter (Imperial College London)H-Index: 5
view all 21 authors...
Abstract Background The prevalence of hypertension among black African patients is high, and these patients usually need two or more medications for blood-pressure control. However, the most effect...
41 CitationsSource
Evidence about the target blood pressure (BP) in patients with resistant hypertension is limited. The present study aimed to assess the efficacy of intensive BP treatment (systolic BP target, <120 ...
7 CitationsSource
#2David A. CalhounH-Index: 69
#3George L. BakrisH-Index: 135
Last. William B. WhiteH-Index: 113
view all 18 authors...
Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a long-acting calciu...
247 CitationsSource
#1Punnaka Pongpanich (King Chulalongkorn Memorial Hospital)H-Index: 1
#2Pasvich Pitakpaiboonkul (King Chulalongkorn Memorial Hospital)H-Index: 1
Last. Paweena Susantitaphong (King Chulalongkorn Memorial Hospital)H-Index: 22
view all 6 authors...
Background The prevalence of hypertension and its associated complications are markedly growing. Most patients need more than one drug to achieve blood pressure (BP) target. However, most guidelines only focus on the first-line treatment. We conducted a meta-analysis to explore the benefits of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) combined with calcium channel blockers (CCBs) on metabolic, renal, and cardiovascular outcomes in hypertensive patie...
6 CitationsSource
#1Bryan Williams (UCL: University College London)H-Index: 149
#2Giuseppe Mancia (University of Milano-Bicocca)H-Index: 166
Last. Ileana DesormaisH-Index: 15
view all 28 authors...
3,004 CitationsSource
: Hypertension is a major preventable risk factor for atherosclerosis and ischemic heart disease. Although modern and effective antihypertensive drugs are available, most patients remain with a suboptimal blood pressure control. Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals - recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >1...
32 CitationsSource
#1Paul K. Whelton (American College of Preventive Medicine)H-Index: 121
#2Robert M. Carey (American College of Preventive Medicine)H-Index: 4
Last. Jackson T. Wright (American College of Preventive Medicine)H-Index: 63
view all 21 authors...
Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health. In 2013, the National Heart, Lung, and Blood Institute (NHLBI) Advisory
2,897 CitationsSource
BackgroundThe ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rat...
6 CitationsSource
#1Chen Chi (Tongji University)H-Index: 7
#2Chenhui Tai (Tongji University)H-Index: 3
Last. Yawei Xu (Tongji University)H-Index: 24
view all 11 authors...
The authors aimed to investigate the superiority of angiotensin system blockade (angiotensin-converting enzyme [ACE] inhibitor/angiotensin receptor blocker [ARB]) plus a calcium channel blocker (CCB) (A+C) over other combination therapies in antihypertensive treatment. A meta-analysis in 20,451 hypertensive patients from eight randomized controlled trials was conducted to compare the A+C treatment with other combination therapies in terms of blood pressure (BP) reduction, clinical outcomes, and ...
13 CitationsSource
Cited By2
#1Erica O. Miller (URMC: University of Rochester Medical Center)H-Index: 4
#2John D. Bisognano (URMC: University of Rochester Medical Center)H-Index: 22
1 CitationsSource